熱門資訊> 正文
OCular Therapeutix错过第一季度街景
2026-05-05 19:12
- Ocular Therapeutix press release (OCUL): Q1 GAAP EPS of -$0.40 misses by $0.07.
- Revenue of $10.8M (+0.9% Y/Y) misses by $1.9M.
- Cash balance of $666.7 million as of March 31, 2026, with expected runway into 2028
More on Ocular Therapeutix
- Ocular Therapeutix, Inc. (OCUL) Presents at 49th Annual Meeting of the Macula Society - Slideshow
- Ocular Therapeutix, Inc. (OCUL) Discusses Phase III SOL-1 Data Highlighting Transformative Durability in Wet AMD Transcript
- Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript
- Ocular Therapeutix Q1 2026 Earnings Preview
- EyePoint sues Ocular over claims related to lead asset
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。